for a decision on marketing authorization for TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the management of fibromyalgia. 1 The above information is preliminary financial ...

The Board of Directors has also approved an increase to CompoSecure’s current share repurchase authorization from $40 ... does not express an opinion or any other form of assurance with respect ...

Preliminary Q4 2024 PEMGARDA™ (pemivibart ... implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the company's Annual Report on Form 10-K ...

This press release and further information about Tonix ... Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with ...

The cash runway is expected to fund the company beyond the August 15, 2025 Prescription Drug User Fee Act (PDUFA) goal date assigned by the U.S. Food and Drug Administration (FDA) for a decision on ...

The legal issue in question here is whether the Trump Administration’s funding pause is an “impoundment” in violation of the separation of powers clauses in the Constitution and under the Impoundment ...

Visteon Corporation (NASDAQ: VC) today reported fourth quarter and full-year 2024 financial results. Highlights include: ...

Indian Prime Minister Narendra Modi has heaped praise on Trump in hopes of avoiding the tariffs that the White House has slapped on other countries.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir—the company’s twice-yearly ...

Q4 2024 Earnings Call Transcript February 12, 2025 Rapid7, Inc. misses on earnings expectations. Reported EPS is $0.48 EPS, ...